NEXTHINK
28.10.2015 08:31:45 CET | Business Wire | Press release
Nexthink®, a pioneer and leader in end-user centric IT Operations Analytics (ITOA), today announced a partnership with Ymor , a leading APM service provider in the Netherlands. Under the agreement, Ymor will be able to provide consulting services, support and implement Nexthink’s IT analytics solutions for its customers.
Ymor unburdens customers through its Ketenbewaking™ service portfolio that protects and optimizes the IT environment by focusing on end-users. By integrating Nexthink’s technology into its offering, Ymor is able to expand and enhance its existing services. In addition to technical, configuration, end-to-end and component monitoring, Ymor can now offer its customers workspace monitoring. Nexthink’s visibility and IT analytics allow Ymor to provide control over the workspace that can lead to fast ROI and financial savings.
"As we strive for ‘end-user happiness,’ workplace monitoring is more important than ever before,” said Martin van den Berge, Director Ymor . “Throughout the workday, most end-users spend at least 5 hours using various applications. Performance issues cause frustration and lead to decreased efficiency for both end-users and the business. Working with Nexthink provides us with an opportunity to measure the end-user experience, to obtain a ‘helicopter view’ of the IT infrastructure, to quickly and easily find the root cause of issues and to achieve the goal of happy end-users.”
Ymor and Nexthink have implemented workplace monitoring with the city of The Hague. Gerard van Lieshout, Sr. Corporate IT Advisor of The Hague : “We use Nexthink to monitor all enterprise desktops, some 7,000 workspaces. By measuring delays, crashes and bottlenecks directly on the desktops, it gives us a better understanding on how our employees use the desktops. This not only allows us to respond better to reported incidents, but also to adjust configurations of the desktops before problems occur.”
“We are excited about the partnership with Ymor and extending our reach in Northern Europe,” said Nathan Wyld, Europe Channel Director at Nexthink . “As a result of this partnership, organisations in the Netherlands can benefit from Nexthink’s IT analytics and Ymor’s outstanding services and support for implementation and optimal use of IT analytics in their environments.”
###
About Ymor:
Ymor is a fast growing and innovative service provider based in Utrecht, which assists the Dutch Top 500 companies in improving the performance of complex IT environments with the goal of unburdening end-users. An organisation may be experiencing problems with performance or availability. It may be building a new application or wish to bring it online. Or there may simply be a need for the complex IT chain to be closely monitored. In all such cases the Ymor ‘Ketenbewaking’ service monitors and optimises the IT environment. Our slogan says it all: “Ymor creates user happiness!”
View source version on businesswire.com: http://www.businesswire.com/news/home/20151028005061/en/
./ContentItem/FormatNexthink and Ymor partnership to meet demand for IT Analytics solutions in the Netherlands and significant customer win: city of The Hague
Contact:
Media contacts:
Nexthink
Victoria Calmon, +33 6
34 77 15 97
victoria.calmon@nexthink.com
www.nexthink.com
or
Ymor
Inge
Vollebregt, +31 610762591
ivollebregt@ymor.nl
www.ymor.nl
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom